# Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer

> **NCT06081777** · — · UNKNOWN · sponsor: **Peking University Cancer Hospital & Institute** · enrollment: 65 (estimated)

## Conditions studied

- NSCLC

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06081777
- **Lead sponsor:** Peking University Cancer Hospital & Institute
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-11-25
- **Primary completion:** 2025-06-01
- **Final completion:** 2025-06-01
- **Target enrollment:** 65 (ESTIMATED)
- **Last updated:** 2023-10-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06081777

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06081777, "Significance of MRD Monitoring in Patients With Potentially Resectable Stage III Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06081777. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*